Methods of treating inflammatory colon diseases

Abstract

A method of treating ulcerative colitis or Crohn's disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells from a placenta or adipose tissue, thereby treating the ulcerative colitis or Crohn's disease.

1 - 21 . (canceled) 
     
     
         22 . A dispenser device comprising:
 a dispenser for intramuscular or intravascular administration of cells, wherein the dispenser contains a composition comprising a population of adherent cells derived from placenta, wherein said adherent cells do not exhibit osteogenic differentiation as assessed by Alizarin Red staining, when subjected to conditions that induce bone marrow cells to undergo osteogenic differentiation.   
     
     
         23 . The dispenser device of  claim 22 , wherein said adherent cells express one or more of CD73, CD90, CD29, or CD105. 
     
     
         24 . The dispenser device of  claim 22 , wherein said adherent cells do not express CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19, or CD79. 
     
     
         25 . The dispenser device of  claim 22 , wherein said adherent cells suppress an immune reaction by suppressing T cell activity. 
     
     
         26 . The dispenser device of  claim 22 , wherein said adherent cells are obtained from a three-dimensional (3D) culture. 
     
     
         27 . The dispenser device of  claim 26 , wherein said three-dimensional (3D) culture comprises a 3D bioreactor. 
     
     
         28 . The dispenser device of  claim 26 , wherein culturing of said adherent cells in said 3D culture comprises perfusion of the adherent cells with a continuous flow of a culture medium. 
     
     
         29 . The dispenser device of  claim 26 , wherein culturing of said adherent cells in said 3D culture occurs for at least 3 days. 
     
     
         30 . The dispenser device of  claim 26 , wherein culturing of said adherent cells in said 3D culture is performed until at least 10% of said adherent cells are proliferating. 
     
     
         31 . The dispenser device of  claim 26 , wherein said adherent cells are cultured from the placenta under 2 dimensional (2D) culturing conditions, prior to culturing of said adherent cells in said 3D culture. 
     
     
         32 . The dispenser device of  claim 22 , wherein said adherent cells are less committed to an adipogenic lineage as compared to adherent cells from bone marrow grown and allowed to differentiate under the same conditions. 
     
     
         33 . The dispenser device of  claim 22 , wherein said adherent cells do not express CD34. 
     
     
         34 . The dispenser device of  claim 22 , wherein the composition further comprises albumin. 
     
     
         35 . The dispenser device of  claim 22 , wherein the composition further comprises a cryopreservent.